Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS stock TRY 4.79, price TRY 4.30, upside +11.4%, quality 41 out of 100. Rating: undervalued. Calculated from audited financials with 25 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 0.7644 TRY – 14.43 TRY · fair‑value band 2.98 TRY – 6.22 TRY · the 4.30 TRY price screens below the 4.79 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS in your weekly email
Every Wednesday you see whether Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide.
Show moreShow less
The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric.
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV for the development of molecule SUL-238 as a treatment for Alzheimer's disease and other neurodegenerative diseases.
In addition, it manufactures, trades, imports and exports of all kinds of human medicines and health products. The company was incorporated in 1997 and is headquartered in Çankaya, Turkey.
Stock analysis
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) currently trades at 4.30 TRY, while our model-based Fair Value estimate is 4.79 TRY, implying the stock looks roughly 10% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 6.48 TRY per share, and 12 of the 25 models we run sit above the 4.30 TRY price.
Bear case: the Dividend Discount group reads lowest at 0.8400 TRY, and 13 of the 25 models stay below the price. Data coverage for this calculation is low.
Scenario range: 2.98 TRY (bear) to 6.22 TRY (bull), the price of 4.30 TRY sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS reported revenue of 19.2B TRY in FY2025 versus 2.5B TRY in FY2021, a compound +66.4%/yr. Reported net income was 814M TRY in FY2025, compounding +27.2%/yr from FY2021.
Key figures
Market cap 19.4B TRY (≈ $386M) Small · P/E ratio 17.2 · P/S ratio 0.87 · EPS (TTM) 0.2500 TRY · Dividend yield 1.1% · Net margin 5.2% · Return on equity 10.5% · Return on assets (EBIT) 12.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 68% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 11%, GENIL screens cheaper than that median.
Fair Value models
Bear2.98 TRYFair Value 4.79 TRYBull6.22 TRY
Price 4.30 TRY · Upside +11.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.1716 TRY per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−0.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+54.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+48.9%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TRY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TRY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−22.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−23.6%
Dividend (yield on the price)1.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 13%
⚠ Revenue per share shrinking 6.6%/yr over ~5Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Turkey: IMF forecast 19.3% a year to 2030, 28.5% from 2016 to 2025) that is about +17.3% a year for the price.
Compare Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 546 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score41 · Bottom 25%
Fair Value upside+11.4% · Above median
Profitability
Return on equity (12 months)10.5% · Above median
Return on assets4.2% · Below median
Net margin (12 months)5.2% · Below median
Operating margin (12 months)11.0% · Above median
Growth and dividend
Revenue growth (quarter YoY)22.9% · Top 25%
Dividend yield (12 months)1.1% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)17.2× · Cheaper than median
P/B1.87× · Pricier than median
P/S (12 months)0.87× · Cheapest 25%
Price / free cash flow (fiscal year)38.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Fair Value". https://www.fairvalue-calculator.com/stock/GENIL
Frequently asked questions
Is Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 4.79 TRY versus a price of 4.30 TRY, about +11% upside (undervalued).
What is the fair value of GENIL?
Our model-based fair value for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 4.79 TRY (as of Nov 5, 2026), built from audited fundamentals. The current price: 4.30 TRY.
What is the quality score of GENIL?
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
Our model-based price target is the fair value of 4.79 TRY (as of Nov 5, 2026) from 25 valuation models. Cautious scenario 2.98 TRY, optimistic scenario 6.22 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS stock forecast for 2026?
Our models put fair value at 4.79 TRY, about +11% upside versus a price of 4.30 TRY (undervalued). Cautious scenario 2.98 TRY, optimistic scenario 6.22 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS reported trailing-twelve-month revenue of about 22.2B TRY (latest available figure, as of Nov 5, 2026).
Does Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS pay a dividend?
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS currently shows a dividend yield of 1.12% relative to its recent price (as of Nov 5, 2026).
What growth is priced into Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
For today's price to be fair in a discounted-cash-flow model, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS would have to grow free cash flow by +40.0 % per year for five years (discount rate 15.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +54.9 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of GENIL use?
Our models discount Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS at 15.7 %: a base by market capitalisation (small), country premium for Turkey. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS that is +40.0 % per year a year over ten years, using the same discount rate (15.7 %) and the same formula as our fair value.
How much growth has Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) delivered so far?
Over the past 5 years revenue at Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS grew +54.9 % a year. The price currently implies +40.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (+40.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The free-cash-flow yield on the price is 2.59 %: that much free cash flow Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS produces per unit of market value. When it exceeds the discount rate of our models (15.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS it is 4.79 TRY per share (as of Nov 5, 2026), against a price of 4.30 TRY. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS stock overvalued or undervalued in 2026?
As of Nov 5, 2026, GENIL trades below its calculated fair value: price 4.30 TRY, fair value 4.79 TRY, a gap of about +11% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GENIL?
No. The price is what the market pays today (4.30 TRY); the fair value is what the company's own numbers justify (4.79 TRY). For Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS the two are 0.4900 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS worth?
The market values Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS at about 19.4B TRY (market capitalisation, as of Nov 5, 2026). Per share that is 4.30 TRY; our models calculate a fair value of 4.79 TRY per share.
What do the bullish and bearish scenarios say about GENIL?
Our models span a range for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS: cautious scenario 2.98 TRY, base 4.79 TRY, optimistic 6.22 TRY per share (as of Nov 5, 2026, price 4.30 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GENIL?
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS trades at a price-to-earnings ratio of 17.2 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4.79 TRY is built from several models across several years. Other multiples: P/B 1.9, P/S 0.9, EV/EBITDA 6.7.
How solid is the balance sheet of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
Balance-sheet figures for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (as of Nov 5, 2026): return on equity 10.5%, debt of 0.02 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is GENIL from its 52-week high?
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS trades at 4.30 TRY, about 68% below its 52-week high of 13.24 TRY and 29% above the low of 3.33 TRY (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4.79 TRY is for.
Which stocks are comparable to Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS stock attractive at the current price?
The data as of Nov 5, 2026: price 4.30 TRY, calculated fair value 4.79 TRY (+11%), Quality Score 41/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GENIL calculated?
We run Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.79 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7% above its aggregate fair value. Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS currently trades 10% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The closing price on Nov 6, 2026 was 4.30 TRY. Our model-based fair value is 4.79 TRY, about +11% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS right now?
A fairly wide model range (2.98 TRY to 6.22 TRY) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
How large is the market capitalisation of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The market capitalisation of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 19.4B TRY (≈ $386M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The price-to-sales ratio of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 0.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
Earnings per share at Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS are 0.2500 TRY (price ÷ EPS = P/E 17.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The dividend yield of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 1.1% (payout 19.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The net margin of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 5.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The return on equity (ROE) of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
On an EBIT basis the return on assets of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 12.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
The operating margin of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 11.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
Revenue at Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is growing +22.9% versus a year earlier (3y avg +52.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL)?
Earnings per share at Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS are growing +377% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) carry?
The net debt of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is 3.0B TRY (fiscal year 2025, ≈ 6.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS in the live analysis
One click puts Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026